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Ewing family tumours (ET) including Ewing’s sarcoma and PNET
are common bone and soft-tissue tumours in adolescents and
young adults. They are characterized by the presence of poorly
differentiated round cells. The majority of ET has a reciprocal
t(11; 22)(q24; q12) chromosomal translocation (Giovannini et al,
1994). Molecular analyses have shown that the rearrangement
fuses the 5¢-half of the EWS gene on chromosome 22 to the 3¢-half
of the Fli1 gene on chromosome 11. This chimaeric gene creates a
fusion protein that has the biochemical characteristics of an aber-
rant transcription factor. NIH3T3 cells expressing the EWS-Fli1
protein formed colonies in soft-tissue agar and tumours in immuno-
deficient mice (May et al, 1993). Targeting the EWS-Fli1 fusion
products of ET cells with antisense RNA results in a loss of
tumorigenicity of ET cells (Ouchida et al, 1995). We previously
reported that inhibition of the expression of EWS-Fli1 by the treat-
ment with antisense oligonucleotides led to the growth arrest of
various ET cell lines both in vitro and in vivo (Tanaka et al, 1997).
These data demonstrated that continuous expression of fusion
products may be needed for the growth of ET. 
In EWS-Fli1 transfected cells, an mE2-C gene (murine cyclin-
selective ubiquitin conjugase) was induced, suggesting that the
biological effects of EWS-Fli1 could be, at least in part, mediated
by transcriptional alteration of genes involved in cell-cycle regula-
tion (Arvand et al, 1998). However, there has been no previous
report indicating any correlation between EWS-Fli1 fusion
product and the expression of cell-cycle regulatory genes. In
mammalian cells, the major regulatory events leading to cell
proliferation occur in the G1-phase of the cell cycle. Since we have
already found that the inhibition of the EWS-Fli1 fusion gene
caused G0/G1 arrest (Tanaka et al, 1997), we hypothesized that the
deranged expression of cyclins, cyclin-dependent kinases (CDKs),
and/or CDK-inhibitors (CKIs) acting in G1 may play critical roles
in the growth and oncogenesis of ET. 
In this study, the effects of EWS-Fli1 antisense oligonucleotides
and forced expression of EWS-Fli1 cDNA on the expression
of G1 cyclins, CDKs and CKIs in ET cells were investigated.
Downregulation and forced expression of the EWS-Fli1 fusion
gene caused dramatic alteration of the expression of G1–S regu-
latory genes. These data suggest that the G1–S regulatory genes may
be in the downstream of the EWS-Fli1 oncogenic transcription
factor. 
MATERIALS AND METHODS 
Materials 
Antisense and sense phosphorothioate oligodeoxynucleotides
purified by high performance liquid chromatography were
purchased from Kurabo Biomedicals Co. (Osaka, Japan). The
sequence of the antisense oligonucleotides was ATCCGT-
GACGCCATTTTCTCTCCT (Tanaka et al, 1997) and the corre-
sponding sense sequence was used as a control. Monoclonal
antibodies to human cyclin D1, cyclin E, p21, p27, and polyclonal
antibodies to mouse cyclin E and p21 were obtained from Santa
Crutz Biotechnology (Santa Cruz, CA, USA). 
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Human PNET cell line SK-N-MC and mouse fibroblast cell line
NIH3T3 were obtained from the American Type Culture Collection
(Rockville, MD, USA). PNKT-1, human PNET cells line, was
established and characterized in our laboratory (Tanaka et al, 1995).
The cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Nissui Pharmaceuticals Co., Tokyo, Japan) supplemented
with 10% fetal bovine serum (FBS) for SK-N-MC and PNKT-1 or
10% calf serum (CS) for NIH3T3 and these cells were then incu-
bated at 37˚C in a humidified atmosphere with 5% of CO2 in the air. 
Cell growth assay 
Cell growth assay was carried out as described (Tanaka et al,
1997). Briefly, various cell lines were seeded on 35-mm culture
dishes at 105 viable cells/dish with 1.5 ml of medium, and incub-
ated at 37˚C. 24 h later, the media were replaced with media
containing antisense or sense oligonucleotides, and the media
supplemented with the oligomers were replaced every 24 h. After
various time intervals, cell numbers were determined using a
haemocytometer. Since the cell viability determined by the trypan
blue exclusion test more than 95% throughout the experiments, the
concentration of oligonucleotides were not toxic. 
Plasmids 
EWS-Fli1 cDNA was isolated from a cDNA library of ET cell
line, SK-N-MC, by PCR amplification using forward primer: 5¢-
GGCAAGCTTAGAGGGAGACGGACGTTGAGAGAACGAG-
3, and reverse primer, 5¢-GGCTCTAGAAGTAAGTGTGCAGG-
ATAAGCATCAG-3¢. The PCR product (~1.6 kb) was subcloned
into the EcoRI and XbaI sites in the pcDNA3.1 (+) mammalian
expression vector (Invitrogen, Groningen, Netherlands), giving the
pcDNA3.1 (+)- EWS-Fli1 construct. 
Transfection of NIH3T3 cells 
NIH3T3 cells were seeded in 6-well plates at a density of 0.5 ´ 105
cells/well and allowed to grow for overnight before transfection.
The cells were washed twice with PBS and a mixture containing 4
ml of FuGENE6 (Behringer) and 1 mg of DNA (pcDNA3.1 (+)
empty vector or pcDNA3.1(+)-EWS-Fli1) in 2 ml DMEM with
10% FBS was overlaid on the cells. Two days after the transfec-
tion, the cells were split in 1:15 dilution and incubated with
0.25 mg ml–1 G418 (Gibco-BRL, Grand Island, NY, USA). The
medium containing G418 was replaced every 3–4 days. Bulk
population of G418-resistent clones was established after 14 days
culture and was used for inoculation to nude mice. 
Tumorigenesis 
The EWS-Fli1 transfected NIH3T3 cells (1 ´ 106) were suspended
in 0.1 ml DMEM with 10% FBS and inoculated subcutaneously
into the back of the nude mice. Tumour growth was monitored and
the established tumour mass was resected, minced and cultured to
isolate the single clone. 
RNA extraction from cells and surgical specimens 
The cells were plated at a density of 2 ´ 104 cells 2 ml–1 of media in
35-mm dishes. The cells were incubated with antisense and sense
oligonucleotides for various periods and total RNA was isolated
from the cells using an RNA-easy kit (Quiagen, Hilden,
Germany). ET tissues used for RNA isolation were frozen in liquid
nitrogen immediately after the resection and total RNA was
extracted using Isogen (Wako, Osaka, Japan) 
RT-PCR 
Two  mg of total RNA were subjected to reverse-transcription
reaction using a Ready-to-Go cDNA synthesis kit (Amersham,
Arlington Heights, IL, USA). Composition of the primers used for
PCR has been described previously (Wang et al, 1996; Tanaka et
al, 1997). PCR reactions were performed in a final volume of 50 ml
for 30 cycles. Each PCR cycle consisted of a heat-denaturation
step at 94˚C for 1 min, a primer annealing step at 55˚C for 30 s,
and an extension step at 72˚C for 1 min. The PCR reaction was
performed within the linear range of amplification determined by a
preliminary study. The PCR products were analysed by 1.5%
agarose gel (Sigma Co., St. Louis, MO, USA). 
Western blot analysis 
Logarithmically growing cells (2–4 ´ 106) at approximately 70%
confluence were harvested and solubilized in an NP-40-based lysis
buffer (20 mM Tris (pH 7.4), 250 mM NaCl, 1.0% NP40, 1 mM
EDTA, 50 mg ml–1 leupeptin, and 1 mM phenylmethylsulphonyl
fluoride). After 10 min of incubation on ice, the cells were
scraped, sonicated, and clarified by centrifugation at 14 000 rpm
for 30 min at 4˚C. Protein quantitation was determined by a
Bradford protein assay (Bio-Rad, Hercules, CA, USA). The
samples were boiled for 5 min and 10 mg of total protein from each
of the samples were run on a 4–12% gradient pre-cast MOPS-
polyacrylamide gel (Novex, San Diego, CA, USA) and blotted
onto a nitrocellulose filter. The filter was pre-treated with TBS
containing 5% dry milk and 0.05% Triton X, for 2 h at room
temperature. Then, the filter was incubated with the appropriate
primary antibodies for 2 h at room temperature. After several
washes, the horseradish peroxidase-conjugated secondary anti-
body (Biosource, Illinois, IL, USA) was added and the filter was
then incubated at room temperature for 1 h. After a final wash,
immunoreactivity of the blots was detected using an enhanced
chemiluminescence system (Amersham). Data were analysed
using an NIH image Ver 1.56. 
Immunofluorescence 
Cells were grown on coverslips and cultured for 24 h in DMEM
with 10% FBS or 10% CS, fixed for 10 min with 4%
paraformaldehyde in phosphate-buffered saline (PBS), and per-
meabilized in 0.1% Triton-X100. Then, the specimens were treated
for 1 h at room temperature with the appropriate primary anti-
bodies. After washing with PBS, the specimens were incubated
with a FITC conjugated anti-mouse or anti-rabbit IgG (Santa Crutz
Biotechnology) for 45 min at room temperature. The samples were
washed, mounted and examined by confocal laser scanning
microscopy. 
Statistical analysis 
All statistical analysis were carried out according to the student’s t-
test. 
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RESULTS 
Effect of antisense oligonucleotides on the expression
of EWS-Fli1 fusion protein 
We synthesized and used the 25 mer antisense oligonucleotides
corresponding to the 34 to 58 base positions of EWS-Fli1 fusion
gene including the ATG initiation codon, as previously described
(Tanaka et al, 1997). SK-N-MC cells treated with EWS-Fli1 anti-
sense oligonucleotides were subjected to Western blot analysis to
detect EWS-Fli1 protein. When the cells were incubated with anti-
sense oligonucleotides for 12 h, the expression of EWS-Fli1 fusion
protein was not significantly affected. However, after 24 h of cul-
tivation, the expression of EWS-Fli1 protein was reduced to approx-
imately 40% that of the control cells and only faint expression was
observed after 48 h of incubation (Figure 1). RT-PCR analysis also
showed similar expression pattern of EWS-Fli1 mRNA, as in
Western blot analysis (data not shown). 
Effect of antisense oligonucleotides on the expression
of cyclin D1 and E 
The G1–S transition is mainly regulated by cyclin D, which binds
to both CDK4 and CDK6, and by cyclin E, which binds to CDK2.
We first investigated the effect of EWS-Fli1 antisense oligo-
nucleotides on the expression of cyclin D1 and cyclin E in SK-N-MC
cells, since it has been reported that cyclin D2 and cyclin D3 are
not implicated in the development of various human tumours
(Qian et al, 1998). Untreated SK-N-MC cells showed remarkable
expression of cyclin D1 protein consistent with the findings of a
recent report (Kovar et al, 1999). However, the expression level of
cyclin D1 was reduced to 50% of that of the control after treatment
with EWS-Fli1 antisense oligonucleotides for 48 h. The expres-
sion of cyclin E protein was slightly reduced after 24 h exposure
with the antisense, and was reduced to approximately 10% of that
of the control at 48 h point (Figure 2A). Treatment with sense
oligonucleotides did not affect the expression of either of these
cyclins at any time point. To further validate the results of Western
blot analysis, protein distribution was analysed by immunofluores-
cence. As shown in Figure 2B, we observed marked nuclear
staining of cyclin E in control SK-N-MC cells, however, incubation
68 kd –
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Figure 1 Western blot analysis of EWS-Fli1 fusion protein in SK-N-MC
cells. The cells were exposed for various periods to the sense or antisense
oligonucleotides against EWS-Fli1 at a concentration of 10 mM. The cell
lysate was extracted and subjected to Western blot analysis. A 68 kDa EWS-
Fli1 fusion protein was detected. Treatment with sense oligonucleotides
treatment did not affect the expression of EWS-Fli1 fusion protein, and the
result at 48 h point is shown. The EWS-Fli1 protein expression was abolished
at 48 h after the treatment 
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Figure 2 Expression of cyclin D1, cyclin E, p21 and p27 proteins in SK-N-MC cells treated with antisense oligonucleotides. Total proteins were obtained at the
indicated time after the addition of antisense or sense oligonucleotides. (A) Western blot analysis showed that the expressions of cyclin D1 and cyclin E were
diminished by treatment with antisense oligonucleotides for 48 h, whereas the treatment with sense oligonucleotides did not affect the expressions. 
(B) Immunofluorescence analysis of SK-N-MC cells using anti-cyclin E antibody. The cells incubated for 48 h with sense oligonucleotides showed strong nuclear
staining of cyclin E, whereas almost no staining was observed after antisense exposure for 48 h. Bar, 50 mm. (C) Western blot analysis revealed that the
expression of p21 and p27 proteins were induced by treatment with antisense oligonucleotides for 48 h. (D) In the immunofluorescence study, remarkable p21
expression within the nucleus was detected after antisense exposure for 48 h, while a very low-level expression of p21 was observed in sense-treated cells. Bar,
50 mm 
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with the EWS-Fli1 antisense oligonucleotides for 48 h totally
abolished the nuclear stainings of cyclin E. Immunofluorescence
analysis of cyclin D1 showed a similar staining pattern to that of
cyclin E (data not shown). 
Effect of antisense oligonucleotides on the expression
of CKIs associated with GI–S transition 
It has been shown that the cyclin-Cdk complex is inactivated by an
excess of CKIs (Sherr and Roberts, 1995). Thus, we examined
whether the protein expression of CKIs could also be altered by the
treatment of SK-N-MC cells with antisense oligonucleotides.
Western blot analysis showed almost no signal of p21 protein in
untreated SK-N-MC cells. However, treatment with 10 mM antisense
oligonucleotides for 24 h induced p21 expression, and a strong
induction of p21 was observed at 48 h after the addition of the anti-
sense. We also investigated the induction of another CKI, p27, in SK-
N-MC cells. The p27 protein was induced in a time-dependent
manner by the antisense treatment, whereas untreated and sense-
treated SK-N-MC cells exhibited no expression of p27 protein
(Figure 2C). Consistent with the results of Western blot analysis, p21
protein was detected by immunohistochemistry in SK-N-MC cells
treated with the antisense oligonucleotides (Figure 2D). The other
important CKI, p16, is frequently mutated in soft-tissue sarcomas.
However, SK-N-MC cells were revealed to have intact p16 (Kovar et
al, 1997), and treated with EWS-Fli1 antisense oligonucleotides did
not affect p16 expression (data not shown). Therefore, the induction
of p21 and p27 proteins may lead to inactivation of the cyclin-Cdk
complex in antisense-treated SK-N-MC cells. 
To investigate the effect of EWS-Fli1 antisense oligo-
nucleotides on other ET cell lines, we treated PNKT-1, a well-
characterized PNET cells expressing EWS-Fli1 fusion protein
(Tanaka et al, 1997). G0/G1 growth arrest with the induction of p21
and p27 was also seen in the PNKT-1 cells treated with antisense
oligonucleotides (data not shown). These results also suggest that
there is a correlation between the downregulation of EWS-Fli1
fusion protein and the alteration of the expression of cell-cycle
regulatory proteins. 
The antisense effect on mRNA expression of G1 cyclins
and CKIs 
To examine the mechanism by which the antisense oligo-
nucleotides modified the protein expression of cyclins and CKIs,
we investigated the alteration of mRNA expression by RT-PCR
analysis. Cyclin D1 and cyclin E mRNA levels in SK-N-MC cells
were dramatically decreased by the treatment with antisense
oligonucleotides for 36 h (Figure 3A). With regard to CKIs, the
p21 mRNA level was increased in SK-N-MC cells following anti-
sense treatment for 24 h and continued to increase for 48 h.
However, treatment with antisense oligonucleotides for 12 h was
not sufficient to produce upregulation of p21 mRNA expression.
An increase in the p27 mRNA expression level was observed
when the cells were treated with antisense for 48 h. The treatment
with sense oligonucleotides had no effect on the mRNA levels of
the cyclins and CKIs even after 48 h of treatment (Figure 3B).
These data suggest that modification of the protein expressions of
the cyclins and CKIs was mediated via induction of mRNAs or a
reduction in the levels of mRNAs brought about by the challenge
of the antisense oligonucleotides. Expressions of the mRNAs of
p16, and CDK2, 4 and 6 were not significantly affected by the
antisense treatment (data not shown). 
Establishment of the EWS-Fli1 transfected NIH3T3
cells, NIH3T3/EWS-Fli1 
To investigate the effect of forced expression of the EWS-Fli1
fusion gene in non-transformed cells, we first tansfected the EWS-
Fli1 cDNA into NIH3T3 cells. The transfected cells were selected
by G418 treatment and bulk population of the transfected cells was
inoculated into nude mice. Transfected cells developed tumour
mass about 3 weeks after the inoculation. The tumour mass was
resected, minced and plated on culture dishes. Then, a single
clone, NIH3T3/EWS-Fli1 was isolated and established. The
expression of EWS-Fli1 in NIH3T3/EWS-Fli1 was confirmed by
RT-PCR analysis (Figure 4A). NIH3T3/EWS-Fli1 cells showed
significantly rapid growth compared to its parental cells (Figure
4B). When NIH3T3/EWS-Fli1 cells were treated with antisense
oligonucleotide, the growth of the cells was significantly inhibit-
ed; the growth inhibition rate was approximately 30% (Figure 4C).
None of the oligonucleotides affected the growth of NIH3T3 cells
(data not shown). 
Expression of G1 cyclins and CKIs in the NIH3T3/EWS-
Fli1 cells 
As shown in Figure 5A, nuclear stainings of cyclin D1 and cyclin
E were detected by immunofluorescence immunohistochemistry,
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Figure 3 Effect of antisense oligonucleotide on mRNA expression of cyclin
D1, cyclin E (A) p21 and p27 (B) in SK-N-MC cells. Two mg of total RNA from
the cells were reverse transcribed and cDNAs were subjected to PCR. The
PCR products were electrophoresed on a 1.5% agarose gel. Ribosomal 18S
RNA amplification served as an internal control. The results of mRNA
expression of the cells treated with sense oligonucleotides for 48 h were also
demonstrated. Consistent with the data shown in Figure 2, the antisense
treatment inhibited mRNA expression of cyclin D1 and cyclin E, and induced
p21 and p27 expression however no expressions of both cyclins were observed in parental
and empty-vector transfected cells. Consistent with the results of
immunohistochemistry, Western blotting analysis indicated the
strong expressions of cyclin D1 and cyclin E in NIH3T3/EWS-
Fli1 (Figure 5B). 
Expression of G1 cyclins and CKIs in the surgical
specimens of ET 
To investigate the expression levels of G1 cyclins and CKIs in
surgical specimens, total RNA was prepared from 4 samples of
resected ET tissues. Reverse-transcribed cDNA from the tissues
was subjected to PCR analysis. All samples showed EWS-Fli1
fusion gene expression (data not shown). As shown in Figure 6,
the tissue specimens strongly expressed cyclin D1 mRNA. Cyclin
E mRNA expression, which was observed in the SK-N-MC cells,
was not detected in the tissues. No samples showed expression of
p21 or p27 mRNA. These observations suggest that an imbalance
772 Y Matsumoto et al 
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Figure 4 Expression of EWS-Fli1 fusion gene and growth of EWS-Fli1
transfected NIH3T3 cells (NIH3T3/EWS-Fli1). (A) Demonstration of the
presence of mRNA of EWS-Fli1 fusion gene in NIH3T3/EWS-Fli1. Total RNA
from the SK-N-MC cells were used as the positive control for EWS-Fli1
expression. NIH3T3/EWS-Fli1 cells indicated clear expression of EWS-Fli1
fusion gene. Ribosomal 18S RNA amplification served as an internal control.
(B) NIH3T3 and NIH3T3/EWS-Fli1 were plated at a concentration of 5 ´ 104
cells in 35 mm dishes. After various time intervals, the cell number was
counted. Points and bars represent mean value and S.D. respectively.
Significantly different from the parent NIH3T3 cells (P < 0.01). All
experiments were carried out in triplicate and repeated twice. (C) Effect of
sense and antisense oligonucleotides on NIH3T3/EWS-Fli1 cell proliferation.
The cells were incubated with 10 mM sense or antisense oligonucleotides
and the number of viable cells was counted after a 36-h incubation. The data
represent the means of the 3 experiments. The bars represent S.D
40
35
30
25
20
15
10
5
0
G
r
o
w
t
h
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
Sense Antisense
NIH3T3/EWS-Fli1
C
B
NIH3T3/EWS-Fli1
NIH3T3 
*
*
0
0
12 24 36 48 h
7
6
5
4
3
2
1
R
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
Cyclin D1
Cyclin D1
Cyclin E
Cyclin E
A
B
NIH3T3
NIH3T3
EWS-Fli1
NIH3T3 NIH3T3/EWS-Fli1
Empty-
vector
Figure 5 Expression of cyclin D1 and cyclin E in NIH3T3/EWS-Fli1 cells.
(A) Immunofluorescence analysis of NIH3T3/EWS-Fli1 using anti-cyclin D1
and cyclin E antibodies. The NIH3T3/EWS-Fli1 showed strong nuclear
staining of both cyclins, whereas almost no staining was observed in NIH3T3
cells. Bar, 50 mm. (B) Western blot analysis of cyclin D1 and cyclin E
expression. The expressions of cyclin D1 and cyclin E were induced by the
trasfection of EWS-Fli1 fusion gene to NIH3T3 cells. Transfection of the
pcDNA3.1(+) empty-vector did not affect the expressions of both cyclins EWS-Fli1 changes expression of G1 regulatory genes 773
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between G1 cyclin and CKIs exists not only in ET cell lines and
EWS-Fli1 fusion gene transfected cells but also in clinical ET
samples. 
DISCUSSION 
Malignant tumours are thought to be a disease with uncontrolled
cell proliferation. There is a growing list of oncogene/tumour
suppressor gene products that regulate the cell cycle, including c-
myc, p53 and RB (Bedi et al, 1994; McGahon et al, 1994). From
the results of our previous study, EWS-Fli1 fusion product is
considered to be involved in cell-cycle progression, especially in
G1–S transition (Tanaka et al, 1997). In this study, we were able to
show that alteration of the expression of G1 regulatory factors
caused by EWS-Fli1 antisense oligonucleotides results in the
G0/G1 arrest of ET cells, and that exogenous transfection of EWS-
Fli1 fusion gene induced the expressions of cyclin D1 and E in
transformed NIH3T3 cells. 
Cell-cycle progression is controlled by a complex of cyclins and
CDKs counterbalanced by CKIs. Cyclin D1 binds and activates
CDK4 (or CDK6). The cyclin D1-CDK4 complex phosphorylates
retinoblastoma protein (pRB) and facilitates cell-cycle progression
from the G1 phase to the S phase. Forced expression of cyclin D1
in rodent mammary cells caused transformation both in vivo and
in vitro (Wang et al, 1994). Cyclin E, a regulatory subunit of
CDK2, is also known to be a factor controlling the G1–S transition.
According to the previous reports, the expression of cyclin E was
highly enhanced in cell lines and surgical specimens of breast
cancer (Keyomarsi et al, 1995). On the other hand, two gene fam-
ilies of mammalian CKIs have been identified: one family includes
p16 (INK4A), p15 (INK4B) and p18 and the other includes
p21Cip, p27Kip and p57. It has been reported that p21, p27 and
p57 inhibit the kinase activity of cyclins D-CDK4 and 6 and the
cyclin E-CDK2 complex in vitro (Gu et al, 1993). Overexpression
of p21 and p27 keeps the RB protein in its active and hypophos-
phorylated form, and causes G0/G1 arrest. In our study, SK-N-MC
cells showed a high steady expression of cyclins D1 and E both at
the mRNA and protein levels. However, the mRNA and protein
expressions of p21 and p27 in the cells were not observed.
Surgical specimens also showed a high level of the expression of
cyclin D1, although p21 and p27 expressions were not detected in
the tissues. Furthermore, forced expression of EWS-Fli1 fusion
gene caused transformation of NIH3T3 cells and the transformed
cells showed strong expressions of cyclin D1 and cyclin E
compared with the parental cells. Since the proper ratio of CDK-
cyclin complex to CKIs is critical for G1 progression, our observa-
tions suggest that an imbalance between the G1 cyclin-CDK
complex and p21 and/or p27 in ET cells and EWS-Fli1 fusion
gene transfected cells may be the reason for uncontrolled prolif-
eration, leading to their transformation. 
We used antisense oligonucleotides against EWS-Fli1 targeting
the sequence including the AUG initiation codon. These antisense
oligonucleotides exert their effect by inhibiting the expression of
the EWS-Fli1 gene. We have already demonstrated that the
antisense oligonucleotides suppressed not only EWS-Fli1, but
also endogenous EWS mRNA expression (Tanaka et al, 1997).
However, the antisense oligonucleotides did not affect the growth
and expression of cyclins and CKIs in other cell lines without the
fusion gene, such as NIH3T3, IMR32 and IMR90 (data not
shown). Therefore, we concluded that the effects of the antisense
oligonucleotides were mainly mediated by the suppression of
EWS-Fli1 expression. 
The effect of antisense oligonucleotides on EWS-Fli1 appeared
when the cells were exposed to antisense oligonucleotides for
more than 24 h. The inhibition of EWS-Fli1 expression was
followed by changes in the expression of cyclins and CKIs.
Treatment of SK-N-MC cells with the antisense oligonucleotides
reduced the mRNA and protein expression of cyclin D1. Coupling
reduction of cyclin E mRNA and protein levels was also observed
after the antisense treatment. The data indicate that the reduction
of cyclin D1 and E by antisense oligonucleotides was due to a
downregulation of mRNA expression. Transfection of EWS-Fli1
fusion gene in NIH3T3 cells induced the expression of cyclin D1
and cyclin E. It has been reported that an ets binding consensus
sequence exists in the promoter region of cyclin D (Albanese et al,
1995), Since EWS-Fli1 act as a transcriptional factor via ets
domain in the Fli1 portion, EWS-Fli1 may transactivate cyclin D1
expression through the ets binding sequence in the promoter. On
the other hand, no ets binding sites have been indentified in the
promoter region of cyclin E gene. Recent studies revealed that the
abundance of cyclin E protein was controlled at transcriptional
level (Botz et al, 1996) and/or stability of mRNA (Oda et al,
1995). Thus, it is possible that induction of cyclin E expression by
EWS-Fli1 may be due to the stabilization of mRNA of cyclin E.
However, exact mechanism of the EWS-Fli1 regulation of G1
cyclins need to be further investigated. 
We also investigated the phosphorylated RB protein (ppRB)
expression in the untreated SK-N-MC cells. Recent study revealed
that the SK-N-MC cells showed only weak expression of ppRB
(Kovar et al, 1997). However, in our study, the expression of ppRB
was observed in untreated and EWS-Fli1 sense oligonucleotides
treated SK-N-MC cells. In addition, treatment with the EWS-Fli1
antisense oligonucleotides caused the reduction of the expression
level of ppRB (data not shown). These findings suggest that the
reduction of the expression level of ppRB might be caused by the
alteration of G1 regulatory genes induced by EWS-Fli1 antisense
treatment. In regard to the ppRB expression of the NIH3T3/EWS-
Fli1 cells, transfection of EWS-Fli1 cDNA induced phosphory-
lated forms of pRB (data not shown) in NIH3T3 cells, which may
be the result of the induction of cyclin D1 and E in these cells. 
Cyclin D1
p21
p27
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Figure 6 RT-PCR analysis of cyclin D1, and p21 and p27 mRNA
expression in biopsy samples of Ewing’s sarcoma. Two mg of total RNA from
biopsy samples were reverse transcribed. The cDNAs were subjected to
PCR and electrophoresed on a 1.5% agarose gel. All surgical specimens
showed mRNA expression of cyclin D1; whereas no mRNA expression of
p21 and p27 was observedThe antisense-treated cells expressed both p21 and p27 to a
remarkable degree, whereas sense-treated cells did not. That
induction occurred in a time-dependent manner both at the mRNA
and protein levels. In our results, logarithmically growing NIH3T3
cells did not show the expressions of p21 and p27. Thus, the
inhibitory effect of the transfection of EWS-Fli1 fusion gene on
the expressions of p21 and p27 could not be confirmed in this
study. It is well known that the p21 gene is transcriptionally activ-
ated by wild-type p53 protein (el-Deiry et al, 1998), suggesting
that p21 plays a key role as a downstream mediator of p53-induced
cell growth arrest. Although surgical specimens of ET usually
reveal to express wild-type p53, it has been reported that the p53
gene is mutated in SK-N-MC cells (Qian et al, 1998). Several
reports have demonstrated the p53-independent regulation of p21
gene expression. Transcription factors, such as STAT protein
(Chin et al, 1996) or vitamin D3 receptor (Liu et al, 1996), act via
direct specific binding to a promoter in p21 gene. In human
prostate carcinoma cell lines lacking wild-type p53, Lovastatim,
an inhibitor of HMG-CoA reductase, transactivated p21 gene
expression through an SP-1-binding site in the promoter and
induced growth arrest in the G1 phase (Lee et al, 1998).
Furthermore, a recent report indicated that the ets-binding sites
were located in the promoter region of p21 (Funaoka et al, 1997).
We investigated the effect of the antisense oligonucleotides on
transactivation of p21 by luciferase assay using the p21 promoter
luciferase reporter construct. When SK-N-MC cells were treated
with antisense oligo, 2 to 3-fold induction of the reporter gene
activity was observed (data not shown). These data suggest that
EWS-Fli1 may be a key regulatory factor for expression of p21 in
ET cells. 
It has been previously demonstrated that the abundance of p27
is regulated by the ubiquitin-proteasome pathway (Pagano et al,
1995), and that the expression level of p27 mRNA remained
unchanged in most cases. Our results indicated, however, that the
administration of EWS-Fli1 antisense oligonucleotides clearly
increased the p27 mRNA and protein expression. The previous
study showed that cAMP-analogue can induce the mRNA and
protein expression of p27 in T lymphocytes (Lalli et al, 1996), and
it also caused cell-cycle block in the G1 phase in CHP-100 Ewing’s
sarcoma cells (Srivastava et al, 1998). In the present study, the
amount of intracellular cAMP was not changed after the treatment
with the antisense oligonucleotides, indicating that the cAMP-
pathway is perhaps not involved downstream of EWS-Fli1 (data
not shown). 
In conclusion, our results demonstrate that suppression of the
EWS-Fli1 fusion protein by the antisense oligonucleotides altered
the expression of G1 regulatory cyclins and CKIs, thereby
resulting in the G1 growth arrest in ET cell lines. Enforced expres-
sion of EWS-Fli1 resulted in transformation of NIH3T3 cells, and
strong induction of cyclin D1 and cyclin E was observed in the
transformed cells. These data suggest that EWS-Fli1 may affect
the G1– S transition in ET cells and that G1 cyclins and CKIs may
be the direct or indirect target of EWS-Fli1 fusion transcription 
factor. 
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